Iron nanoparticles could supercharge radiation against cancer
NCT ID NCT07491783
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an experimental iron nanoparticle injection (CNSI-Fe) given directly into tumors along with standard radiotherapy. The goal is to see if the combination shrinks tumors better than radiation alone. The study will enroll 52 adults with head and neck cancer or soft tissue sarcoma who are candidates for radiation therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- carbon nanoparticle iron suspension (CNSI-Fe)
- What this could lead to
- If it works, this could offer a new way to boost radiotherapy's effect on solid tumors, potentially shrinking tumors more effectively.
- What could go wrong
- This is an early Phase 2 trial with only 52 people, so results may not apply widely. The injection is experimental and could cause side effects like pain or swelling at the injection site.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can a glowing drug light up head and neck tumors?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Ancient Mind-Body practice tested as fatigue fighter for men after cancer
- New drug combo aims to shrink oral cancers before surgery
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors